Wan-Hsin Lin

Wan-Hsin Lin

Auto-generated profile, based on publicly available information

Wan-Hsin Lin

Department of Cancer Biology, Mayo Clinic, Florida , Jacksonville, FL

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
WLWan-Hsin Lin
Wan-Hsin Lin
RFRyan W. Feathers
Ryan W. Feathers
LCLisa M. Cooper
Lisa M. Cooper
LLLaura J. Lewis-Tuffin
Laura J. Lewis-Tuffin
JCJiaxiang Chen
Jiaxiang Chen
PAPanagiotis Anastasiadis
Panagiotis Anastasiadis
Glioblastomas (GBM) are aggressive tumors that lack effective treatments. Here, we show that the Rho family guanine nucleotide exchange factor Syx promotes GBM cell growth both in vitro and in orthotopic xenografts derived from patients with GBM. Growth defects upon Syx depletion are attributed to prolonged mitosis, increased DNA damage, G2/M cell cycle arrest, and cell apoptosis, mediated by altered mRNA and protein expression of various cell cycle regulators. These effects are phenocopied by depletion of the Rho downstream effector Dia1 and are due, at least in part, to increased phosphorylation, cytoplasmic retention, and reduced activity of the YAP/TAZ transcriptional coactivators. Furthermore, targeting Syx signaling cooperates with radiation treatment and temozolomide (TMZ) to decrease viability in GBM cells, irrespective of their inherent response to TMZ. The data indicate that a Syx-RhoA-Dia1-YAP/TAZ signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in GBM and argue for its targeting for cancer treatment.

3 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
WLWan-Hsin Lin
Wan-Hsin Lin
RFRyan W. Feathers
Ryan W. Feathers
LCLisa M. Cooper
Lisa M. Cooper
LLLaura J. Lewis-Tuffin
Laura J. Lewis-Tuffin
JSJann N. Sarkaria
Jann N. Sarkaria
PAPanagiotis Anastasiadis
Panagiotis Anastasiadis
Glioblastomas (GBM) are aggressive tumors that lack effective treatments. Here, we show that the Rho family guanine nucleotide exchange factor Syx promotes GBM cell growth both in vitro and in orthotopic GBM patient-derived xenografts. Growth defects upon Syx depletion are attributed to prolonged mitosis, increased DNA damage, G2/M cell cycle arrest, and cell apoptosis, mediated by altered mRNA and protein expression of various cell cycle regulators. These effects are phenocopied by depletion of the Rho downstream effector Dia1 and are due at least in part to increased cytoplasmic retention and reduced activity of the YAP/TAZ transcriptional coactivators. Further, targeting Syx signaling cooperates with radiation treatment and temozolomide (TMZ) to decrease viability in GBM cells irrespective of their inherent response to TMZ. Taken together, the data indicate that a Syx-RhoA-Dia1-YAP/TAZ signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in GBM and argue for its targeting for cancer treatment. One Sentence Summary: Syx promotes growth and therapy resistance in glioblastoma.

14 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KKKilannin Krysiak
Kilannin Krysiak
ADArpad M Danos
Arpad M Danos
SKSusanna Kiwala
Susanna Kiwala
JMJoshua F McMichael
Joshua F McMichael
ACAdam C Coffman
Adam C Coffman
MGMalachi Griffith
Malachi Griffith
CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org ) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. With nearly 300 contributors, CIViC contains peer-reviewed, published literature curated and expert-moderated into structured data units ( Evidence Items ) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new evidence types (predisposing, oncogenic and functional). The growing CIViC knowledgebase distributes clinically-relevant cancer variant data currently representing >2500 variants in >400 genes from >2800 publications.

15 June 2026 in Neuro-Oncology
Verified
Journal Article
Open access
DGDiogo Moniz Garcia
Diogo Moniz Garcia
WLWan-Hsin Lin
Wan-Hsin Lin
DWDaniel P Wickland
Daniel P Wickland
EJErik Jessen
Erik Jessen
EMErik Middlebrooks
Erik Middlebrooks
AQAlfredo Quinones-Hinojosa
Alfredo Quinones-Hinojosa
Background: Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods: Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results: Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions: This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.

26 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
RBRyan J Boyd
Ryan J Boyd
TOTien L. Olson
Tien L. Olson
JZJames D. Zook
James D. Zook
MAManuel Aceves
Manuel Aceves
DSDerek Stein
Derek Stein
PFPetra Fromme
Petra Fromme
Structural discovery of guanine nucleotide exchange factor (GEF) protein complexes is likely to become increasingly relevant with the development of new therapeutics targeting small GTPases and development of new classes of small molecules that inhibit protein-protein interactions. Syx (also known as PLEKHG5 in humans) is a RhoA GEF implicated in the pathology of glioblastoma (GBM). Here we investigated protein expression and purification of ten different human Syx constructs and performed biophysical characterizations and computational studies that provide insights into why expression of this protein was previously intractable. We show that human Syx can be expressed and isolated and Syx is folded as observed by circular dichroism (CD) spectroscopy and actively binds to RhoA as determined by co-elution during size exclusion chromatography (SEC). This characterization may provide critical insights into the expression and purification of other recalcitrant members of the large class of oncogenic — Diffuse B-cell lymphoma (Dbl) homology GEF proteins. In addition, we performed detailed homology modeling and molecular dynamics simulations on the surface of a physiologically realistic membrane. These simulations reveal novel insights into GEF activity and allosteric modulation by the plekstrin homology (PH) domain. These newly revealed interactions between the GEF PH domain and the membrane embedded region of RhoA support previously unexplained experimental findings regarding the allosteric effects of the PH domain from numerous activity studies of Dbl homology GEF proteins. This work establishes new hypotheses for structural interactivity and allosteric signal modulation in Dbl homology RhoGEFs.

26 November 2022 in Cancer Genetics
Verified
Journal Article
Closed access
JSJason Saliba
Jason Saliba
ACAlanna J. Church
Alanna J. Church
ADArpad Danos
Arpad Danos
LFLarissa V. Furtado
Larissa V. Furtado
TLTheodore Laetsch
Theodore Laetsch
ARAngshumoy Roy
Angshumoy Roy